Discover Great Companies Discover Great Clients
Popularity  13.6万   |   Followers  64   |   Likes  27   |   Feedback  47 Claim this company

Serving human pharmaceutical and health undertakings

No.109 Chongqing Popularity Ranking No.9 Jiangbei District No.1 Healthcare Healthy No.1 Vaccines No.1 Jian Kang Jiao Yu / Training No.1 Yu Fang Bao Jian No.1 Jian Kang Sheng Huo No.1 Health Examination No.2 Emergency No.3 Jian Kang Chan Industries No.3 Sheng Ming Ke Xue No.3 Sheng Wu Ke Ji / Biotechnology Engineering No.4 Innovative Drugs No.4 Biotechnology Pharmaceuticals 创新型企业 守合同重信用企业 文明单位 副会长单位 高新技术企业 发明专利
More

Company Overview

  • Nature: listed company Size: 1000-4999 employees Founded: 31年
  • Industry: pharmaceutical/biotechnology 、 beauty/healthcare 、 life services
  • Full name: Chongqing Zhifei Biological Products Co., Ltd.。

Development Stage

  • Stage: 定向增发, 23.5亿人民币。
  • Ranking: Ranked #109 in Chongqing by popularity Ranked #1 in Chongqing Healthcare Healthy Company by popularity Ranked #1 in Chongqing Vaccines Company by popularity Ranked #1 in Chongqing Jian Kang Jiao Yu / Training Company by popularity Ranked #1 in Chongqing Yu Fang Bao Jian Company by popularity
  • Honors: 2025中国500强 2024中国民营500强 创新型企业 守合同重信用企业 According to algorithm
  • News: 2026-10-26:智飞生物:第三季度归母净利润1.25亿元,同比增长117.36%。
  • Salary: 71.6% of positions earn 10-20K, In 2026 vs last yeargrew by 26%.。Master's salary: ¥14.1K, Doctorate salary: ¥40.0K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 60%, "Computer/Network/Technology": 8.5%, "Other (R&D and Technical)": 0.8%。
  • Recruiting: In 2026 vs 2025decreased by 20%. Demand for highly educated talent: Master's: 15, Doctorate: 3.
  • Requirement: Education: 本科 leads with 72.4%. Experience: 3-5年 leads with 43.5%.
  • Region: Distributed across 34 regions, 重庆: 9.5%, 成都: 5.8%, 郑州: 5.5%, 济南: 4.7%.

About the Company

[Summary] Serving human pharmaceutical and health undertakings

Chongqing Zhifei Biological Products Co., Ltd. was established in 2002, and is a biopharmaceutical enterprise integrating R&D, production, sales, distribution, and import/export of vaccines and biological products. Its registered capital is RMB 2,393,789,747, and total assets are RMB 45.937 billion. In 2024, it generated revenue of RMB 26.07 billion and paid taxes of RMB 5.089 billion. In the first half of 2025, revenue was RMB 4.919 billion with taxes of RMB 767 million. Cumulative taxes paid exceed RMB 28 billion. The Zhifei system (including Zhirui Investment) employs over 10,000 people. In September 2010, the company was listed on the Shenzhen Stock Exchange, becoming the first private vaccine enterprise listed on the ChiNext board. It has 6 subsidiaries and 2 associated companies. Adhering to the corporate tenet of "social benefits first, corporate benefits second" and the core values of "six firsts, six seconds", the company is committed to the mission of "preventing undiseased, curing diseased, and safeguarding human health", striving to become a leading biopharmaceutical enterprise. In R&D, the company adopts an innovation strategy of "independent R&D as the mainstay, collaborative R&D as a supplement, and investment incubation as a complement", and adheres to the development approach of "internationalization of project sources, precision in project selection, pipelining of project development, and localization of project production". It has constructed a comprehensive three-dimensional R&D platform and participated in more than 60 major projects including the National Major New Drug Creation Special Project. It has established three R&D and production bases in Beijing, Anhui, and Chongqing, and multiple R&D centers in Beijing, Shanghai, and other locations. Currently, the company has announced 34 R&D projects in progress, built an eight-category product matrix covering meningococcal, pneumococcal, and enteric vaccines, and established nine technology platforms, including genetic recombination, multi-combination multivalent, mRNA vaccine, and human diploid cell line platforms. The recombinant novel coronavirus vaccine (CHO cell) developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences was included in the Ministry of Science and Technology's key special project on "public safety risk prevention and emergency technical equipment", becoming the first internationally approved recombinant subunit COVID-19 vaccine, contributing positively to the prevention and control of the pandemic. The company's tuberculosis dual products have been launched sequentially; EC has been recommended by the World Health Organization (WHO) for the diagnosis of tuberculosis infection, enabling precise screening of Mycobacterium tuberculosis infection, while Weika has good preventive effects for high-risk populations and latent TB infection and also effective adjuvant therapy for active TB, making a significant impact on the fight against tuberculosis. At the same time, the company is expanding in the biomedical and health industries, deepening presence in oncology, autoimmune diseases, metabolic diseases, neurodegenerative diseases, and cardiovascular diseases, forming a three-dimensional development platform of "prevention + treatment". In March 2025, the company incorporated Chenan Biologics into the listed company, further deepening and expanding its R&D layout, extending business from vaccines to metabolic diseases, and formally entering the therapeutic biopharmaceutical field, opening new prospects for the company's "cure existing diseases" strategy. In marketing, the company has established a comprehensive and in-depth service network, providing continuous, efficient, and comprehensive quality services to 31 provinces, autonomous regions, and municipalities directly under the central government across the country, including more than 300 prefecture-level cities, over 2,600 district and county areas, and more than 30,000 primary health service sites (township vaccination points and community clinics). By self-building a cold chain system compliant with national GSP requirements, the company ensures seamless cold chain for vaccine storage and transportation. Through refrigerated vehicles equipped with real-time temperature monitoring systems and remote automatic alarm capabilities, it delivers vaccine products in high quality to various disease prevention and control centers. After more than two decades of development, the company has been recognized by the community. Its chairman was ranked 9th in Forbes China's 2021 Best CEO List, received the State Council Special Allowance, the National Advanced Individual in Fighting the COVID-19 Pandemic in the Private Economy, the Fifth Outstanding Builder of Socialism with Chinese Characteristics, and other awards. The company was selected into the 2025 Fortune China 500, the 2022 Forbes Global 2000, the TOP 10 global vaccine companies, the 2021 China Private Enterprise Social Responsibility Excellent Case by the All-China Federation of Industry and Commerce, ranked first among 22 national excellent cases, and listed in the China Top 500 Private Enterprises. It has received honors such as the People's Enterprise Social Responsibility Award, the 2023 China Manufacturing Listed Companies Social Responsibility Five-Star Gold Award, the National Advanced Enterprise in Pandemic Response, the National Double-Strength Hundred-Good Party Organization of Non-Public Enterprises, the National Contract-Abiding and Credit-Worthy Enterprise, the National Commercial Integrity Pilot Enterprise, the China Capital Annual Conference A-share Best Listed Companies Top 20, and the Chongqing May Day Labor Award.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Zhifei Biologics Financing History (2 rounds)

Manage
定向增发
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 23.5亿人民币
  • Investor: 投资方未披露

Zhifei Biologics How Fast Is Hiring Growing? (240 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Down 52%
  • 2024: Up 71%
  • 2023: Up 48%
  • 2022: Up 78%
Zhifei Biologics Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Zhifei Biologics Campus Recruitment & Advanced Degree Talent Demand
Graduates 2 Interns 3 Master's 15 Doctorate 3
Note: How fast is hiring at Chongqing Zhifei Biological Products Co., Ltd. growing? Zhifei Biologics2026: 523 openings (down 20%), 2025: 656 openings (down 52%), 2024: 1364 openings (up 71%), 2023: 797 openings (up 48%), 2022: 539 openings (up 78%), 2021: 302 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Zhifei Biologics Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Down 57%
  • 2024: Up 250%
  • 2023: Down 67%
  • 2022: Up 50%
Zhifei Biologics Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Chongqing Zhifei Biological Products Co., Ltd. growing? Zhifei BiologicsMaster's recruitment over the years: 2025: 3 openings (down 57%), 2024: 7 openings (up 250%), 2023: 2 openings (down 67%), 2022: 6 openings (up 50%), 2021: 4 openings. Zhifei Biologics master talent ranking in Chongqing: #44, Zhifei Biologics master salary mostly around 10-20K.

Zhifei Biologics Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
Zhifei Biologics Doctoral Hiring by Year: 2026
* Hiring was generally low during 2020-2022 due to the pandemic
No.29
Doctoral Demand Ranking in Chongqing 򀀩
¥30-50K
Doctoral Salary 򀀩
How fast is doctoral hiring at Chongqing Zhifei Biological Products Co., Ltd. growing? Zhifei BiologicsDoctorate recruitment over the years: 2026: 3 openings (up 800%), 2023: 1 openings (down 67%). Zhifei Biologics doctorate talent ranking in Chongqing: #29, Zhifei Biologics doctorate salary mostly around 30-50K.

Zhifei Biologics R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Chongqing Zhifei Biological Products Co., Ltd.? Based on an analysis of Zhifei Biologics's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 60%, "Computer/Network/Technology": 8.5%, "Other (R&D and Technical)": 0.8%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 0.5%, "Scientific Research": 0.5%. For reference only.

Zhifei Biologics — What Are the Salaries Like? (658 records)

Manage
salary range: 3K - 50K, 71.6% of roles pay ¥10-20K
Note: salary statistics are based on 658 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Chongqing Zhifei Biological Products Co., Ltd.?Zhifei Biologics71.6% of positions earn 10-20K, Fresh graduate salary: ¥7.4K。Chongqing salary ranking top 10,Sales average salary ¥16.5K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Zhifei Biologics

(More)
Are salaries high at Chongqing Zhifei Biological Products Co., Ltd.? We provide: Pharmaceutical Sales Representative, 临床, Product Manager, Promotion Specialist, Medical Manager, Sales, Provincial Manager, Quality, Provincial Manager, Business Manager, Project Manager, Finance Specialist, Regional Manager, Intern, Marketing, Management Specialist, 医学专员, Medical Science Liaison, Management Manager, BP. Click to view detailed salary analysis by job.

Zhifei Biologics — Fortune 500? (More)

Yes, ranked in 中国500强:

  • NO.499 2025中国500强 >
  • NO.319 2024中国500强 >
  • NO.356 2023中国500强 >

Yes, ranked in 中国民营500强:

  • NO.232 2024中国民营500强 >
  • NO.318 2023中国民营500强 >
  • NO.391 2022中国民营500强 >

Zhifei Biologics honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • Sales
    67.9% of total 67.9%
  • Medical & Health/Beauty & Healthcare
    60% of total 60%
  • Business Management
    18.3% of total 18.3%
  • Marketing/PR/Media
    10.3% of total 10.3%

Education

  • 本科
    72.4% of total 72.4%
  • 大专
    21.5% of total 21.5%
  • 硕士
    4.1% of total 4.1%
  • 不限
    1.5% of total 1.5%

Experience

  • 3-5年
    43.5% of total 43.5%
  • 1-3年
    26.8% of total 26.8%
  • 不限
    17.3% of total 17.3%
  • 5-10年
    11.4% of total 11.4%
View Detailed Analysis

What does Chongqing Zhifei Biological Products Co., Ltd. require? Who is Zhifei Biologics hiring? Zhifei Biologics recruitment: Sales占比最多占67.9%,其次是Medical & Health/Beauty & Healthcare占60%. What education can get in at Zhifei Biologics? 本科占比最多占72.4%,其次是大专占21.5%. High education required at Zhifei Biologics? 硕士占4.1%,博士占0.5%. Work experience required at Zhifei Biologics? 3-5年占比最多占43.5%,其次是1-3年占26.8%. Where are the job locations at Zhifei Biologics? 重庆占比最多占9.5%,其次是成都占5.8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 239,378.9747万(元)
Legal Representative: 蒋仁生
Date Established:
Credit Code: 91500000203049808L
Registered Address: 重庆市江北区庆云路1号50层

Partners & Suppliers

提供分装及包装设备 Source
供应商 制药企业客户
国药控股分销中心分销智飞生物HPV疫苗等 Source
合作客户 疫苗
默沙东授权智飞生物独家代理其疫苗产品 Source
供应商 分销渠道
南京医药作为智飞生物肺炎疫苗及重组蛋白疫苗江苏分销商 Source
合作客户 生物制品
采购色谱填料用于疫苗(如HPV疫苗、重组蛋白疫苗)的分离纯化 Source
供应商 疫苗

People who follow Zhifei Biologics also follow

Zhifei Biologics Competitors (Similar Companies)

“Pharmaceutical Custom R&D and Manufacturing”
体外诊断试剂 诊断试剂 试剂 抗体
“To provide patients with trustworthy and affordable innovative biologi”
“Virtue over the world, medicine benefits all”
“Home furnishing brand operator”
制冷 压缩机 精密铸造 空调压缩机
“Top 10 of China Light Industry Plastic Industry”
“Professional manufacturer and service provider of cranes”
“电连接器、连接器组件及精密智能产品”
“To produce more affordable and effective medicines for the Chinese peo”
“International engineering general contracting, import and export trade”
医疗服务 眼科 医院 医疗护理
电动推杆 驱动器 自动化 工业自动化
“A comprehensive provider and advanced manufacturer of global motion co”
“A comprehensive pharmaceutical enterprise integrating drug R&D, produc”

Discover Great Companies, Discover Great Clients

重庆公司名录 重庆“Jiangbei District”公司名录 重庆“生物制品”公司名录 重庆“生物制药”公司名录 重庆“生物医药”公司名录 重庆“药物研发”公司名录 重庆“医疗器械”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates